DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR NIACIN
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
All Clinical Trials for Niacin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000482 | Coronary Drug Project | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1965-04-01 | To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction. |
| NCT00000512 | Familial Atherosclerosis Treatment Study | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1984-01-01 | To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography. |
| NCT00000512 | Familial Atherosclerosis Treatment Study | Completed | University of Washington | Phase 3 | 1984-01-01 | To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography. |
| NCT00000539 | Arterial Disease Multifactorial Intervention Trial (ADMIT) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1992-09-01 | To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Niacin
Condition Name
Condition MeSH
Clinical Trial Locations for Niacin
Trials by Country
Clinical Trial Progress for Niacin
Clinical Trial Phase
Clinical Trial Sponsors for Niacin
Sponsor Name
